AbbVie 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- AbbVie reported third-quarter 2026 adjusted earnings per share of $3.82, 7 cents above the guidance midpoint, and total net revenues of $17.4 billion, up 10.5% operationally and $200 million above expectations.
- Nine key products delivered double-digit growth; immunology revenues approached $9.2 billion, up 16.6% operationally, neuroscience revenues were nearly $3.4 billion, up 19.5%, oncology revenues were $1.7 billion, up 0.9%, and aesthetics sales were nearly $1.2 billion, down 1.8%.
- Skyrizi sales were nearly $5.8 billion, up 22.9% operationally, and Rinvoq sales were $2.7 billion, up 24.3%; Humira sales were $683 million, down 30.6%.
- Vraylar sales were nearly $1.1 billion, up 14.3%; Botox therapeutic revenues were approximately $1.1 billion, up 9.8%; Ubrelvy sales were $449 million, up 26.9%; and Qulipta revenues were $398 million, up more than 38%.
- Venclexta sales were $803 million, up 10.7%, while Imbruvica sales declined 26.1%; Botox Cosmetic revenues were $669 million, up 4.1%, and Juvederm sales were $222 million, down 11.8%.
- Adjusted operating margin was 48.7% of sales, including a 1.2% unfavorable impact from acquired IPR&D expense; adjusted net interest expense was $688 million and the adjusted tax rate was 13.6%.
- AbbVie reported a cash balance of $10.8 billion at the end of September and approximately $14 billion of free cash flow in the first nine months of the year, including nearly $2.7 billion of Skyrizi royalty payments.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, and thank you for standing by. Welcome to the AbbVie Third Quarter 2026 Earnings Conference Call. All participants will be able to listen only until the question-answer portion of this call. You may ask a question by pressing star 1 on your phone. Today's call is also being recorded. If you have any objections, you may disconnect at this time. I would now like to introduce Ms. Liz Shea, Senior Vice President, Investor Relations.
Good morning, and thanks for joining us. Also on the call with me today are Rob Michael, Chairman and Chief Executive Officer, Jeff Stewart, Executive Vice President, Chief Commercial Officer, Roopal Thakkar, Executive Vice President, Research and Development, Chief Scientific Officer, and Scott Reents, Executive Vice President, Chief Financial Officer. Before we get started, I'll note that some statements we make today may be considered forward-looking statements based on our current expectations. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in our forward-looking statements. Additional information about these risks and uncertainties is included in our SEC filings. AbbVie undertakes no obligation to update these forward-looking statements except as required by law. On today's conference call, non-GAAP financial measures will be used to help investors understand AbbVie's business performance.
These non-GAAP financial measures are reconciled with comparable GAAP financial measures in our earnings release and regulatory filings from today, which can be found on our website. Following our prepared remarks, we'll take your questions. With that, I'll turn the call over to Rob.
Thank you, Liz. Good morning, everyone, and thank you for joining us. AbbVie continues to perform above our expectations, with another quarter of outstanding results. We are delivering top-tier sales and earnings growth and making significant progress advancing our pipeline. Given the strength of our business and our promising outlook, we are once again raising our full-year guidance and increasing our quarterly dividend. Turning to our third-quarter performance, we achieved adjusted earnings per share of $3.82, which is $0.07 above our guidance midpoint. Total net revenues were $17.4 billion, beating our expectations by $200 million and reflecting robust sales growth of more than 10%. This includes nine key products that delivered double-digit growth.
Based on the strong performance across our business, including SKYRIZI, RINVOQ, VRAYLAR, UBRELVY, QULIPTA, and VENCLEXTA, we are raising our full-year revenue guidance by $200 million and have now raised total revenue by $800 million since the start of the year. Further underscoring our confidence in our long-term outlook, today we announced a 5.2% increase in our quarterly cash dividend, beginning with the dividend payable in February 2027. Since inception, we have grown our quarterly dividend by more than 350%. Turning now to R&D, we are making excellent progress advancing our pipeline to help drive growth in the 2030s and beyond. In immunology, we completed the acquisition of Apogee Therapeutics, adding multiple differentiated assets in dermatology, respiratory, and other related inflammatory diseases with significant sales potential. The lead asset, zumilokibart, will be starting phase III development in atopic dermatitis later this year.
Also in immunology, we received U.S. approval for SKYRIZI subQ induction in Crohn's. This new dosing option demonstrated exceptional efficacy and further strengthens SKYRIZI's robust growth outlook. We also continue to make substantial progress with our strategy to combine SKYRIZI with complementary mechanisms to further elevate the standard of care for patients with IBD. We have now started a large phase II-B program in both Crohn's and UC, with SKYRIZI plus our alpha-4 beta-7 ABBV-382, as well as SKYRIZI plus our TL1A ABBV-701. Moving to neuroscience, we recently expanded our Parkinson's portfolio with the FDA approval of JUVMO. JUVMO provides physicians and patients with a meaningful new treatment option and represents a sizable commercial opportunity for AbbVie. Along with VYALEV and DUOPA, we expect our Parkinson's therapies to collectively deliver peak sales of more than $5 billion. We are also making excellent progress with our oncology pipeline.
etentamig in multiple myeloma has demonstrated very high efficacy, as well as differentiated safety and convenience. We have now submitted our application for etentamig in the U.S. and anticipate approval in 2027. In addition, we reported positive phase III data for EPKINLY in frontline DLBCL and expect regulatory submission next year. In summary, we are delivering strong execution across our business and see numerous opportunities to drive long-term growth. With that, I'll turn the call over to Jeff for additional comments on our commercial highlights.
Jeff? Thank you, Rob. I'll start with the quarterly results for immunology, which delivered total revenues approaching $9.2 billion, reflecting operational sales growth of 16.6%.
SKYRIZI and RINVOQ continue to exceed our expectations, demonstrating robust growth across all indications. SKYRIZI total sales were nearly $5.8 billion, up 22.9% on an operational basis. In psoriasis, SKYRIZI prescription trends remain very strong. Our recent oral competition is not having a substantive impact on our in-play patient share, with SKYRIZI continuing to capture roughly one out of every two new or switching psoriasis patients.
We believe that SKYRIZI's best-in-class profile, which delivers 100% skin clearance for the majority of psoriasis patients, high durability of response, very convenient quarterly dosing, exceptional long-term safety, and robust joint protection in psoriatic arthritis with strong data through five years of treatment, sets a very high bar relative to other therapies on the market or in development for psoriasis. In IBD, SKYRIZI is growing very robustly as well, and continues to capture half of the new patient starts in the class. We are very excited to be launching the subcutaneous induction dosing for Crohn's disease, which further strengthens our competitive position. The data supporting this new delivery is striking, including impressive rates of endoscopic response and remission, particularly for CD patients in the frontline setting.
This efficacy is clearly differentiated relative to our own SKYRIZI IV formulation, and will allow us to be very competitive versus all induction therapies available for Crohn's today. Our subcu induction regimen is delivered with the same on-body injector as our IBD maintenance dose, which has received very favorable feedback from gastroenterologists and patients both, including overall ease of use, dosing speed, and comfort. While access typically takes a couple months to ramp, our commercial and medical teams have already hit the ground running, and we expect the subcu induction will accelerate our new patient share in Crohn's over the next several quarters. Overall, we remain very competitively positioned in gastro and psoriatic disease. We are raising our SKYRIZI full-year sales guidance for the third time this year, and we see a substantial opportunity for both market and share growth well into the next decade.
Turning now to RINVOQ, which delivered global sales of $2.7 billion, reflecting operational growth of 24.3%. RINVOQ is also exceeding our expectations, with particularly strong momentum in both RA and IBD, where we continue to see growing in-play patient share. We are also excited for the indication expansion opportunities in dermatology, with commercialization of RINVOQ for vitiligo and alopecia areata underway already in Europe, and approvals expected for both diseases in the U.S. over the next several months. Recall these two new indications combined are expected to contribute nearly $2 billion of peak sales. Lastly, in immunology, HUMIRA global sales were $683 million, down 30.6% on an operational basis, reflecting continued biosimilar competition. Moving to neuroscience, where we continue to outperform expectations across our leading portfolio. Total revenues were nearly $3.4 billion, up 19.5% on an operational basis.
In psychiatry, VRAYLAR global sales were nearly $1.1 billion, up 14.3%. Performance in both bipolar disorder and adjunctive MDD continues to be very strong, reflecting VRAYLAR's well-defined profile in terms of dosing flexibility, low sedation, and the ability to treat a full spectrum of symptoms. In migraine, we continue to deliver robust sales growth, driven by share gains and underlying market growth as well. BOTOX Therapeutic global revenues were approximately $1.1 billion, up 9.8%. UBRELVY global sales were $449 million, up 26.9%, and QULIPTA global revenues were $398 million, up more than 38%. Menstrual migraine prevention represents another opportunity to further strengthen our leading CGRP profiles. Recent positive data for QULIPTA and forthcoming results for UBRELVY in this new potential indication could support approval and commercialization in late 2027. We also have substantial momentum in Parkinson's disease.
VYALEV total sales were $286 million, reflecting double-digit growth. We remain on track to exceed $1 billion in revenue this year. We are also launching JUVMO, another exciting new treatment for patients with Parkinson's. JUVMO selectively activates the D1/D5 dopamine receptors involved in motor control, and can be prescribed now as both a monotherapy in Parkinson's, as well as an add-on to standard of care. Given JUVMO's distinct profile, including strong durable motor control and low rates of debilitating side effects, such as impulse control disorder, somnolence, and dyskinesia, it represents a sizable commercial opportunity. Sales for JUVMO are expected to ramp gradually over the next several quarters as we work to establish commercial and Medicare coverage, which is expected to be more broadly available starting in 2028. Turning now to oncology, total revenues were $1.7 billion, up 0.9% on an operational basis.
VENCLEXTA is performing very well, especially in CLL, as combination use with BTK inhibitors is a preferred fixed-duration treatment globally. Total sales were $803 million, up 10.7%. Continued double-digit sales growth from ELAHERE and EPKINLY also helped to offset the expected revenue decline for IMBRUVICA, which was down 26.1% due to IRA pricing and competitive share pressure. I am also very excited for our developing portfolio in hematology, following positive data for both etentamig in multiple myeloma and EPKINLY in frontline DLBCL. We anticipate their potential approvals will be an important catalyst for next year and immediately supported by our existing commercial resources, including a substantial heme sales force and medical affairs team. Lastly, in aesthetics, global sales were nearly $1.2 billion, down 1.8% on an operational basis. BOTOX Cosmetic total revenues were $669 million, up 4.1% operationally, reflecting improving market growth globally.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
17 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
